|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The YKL-40 coding chitinase 3-like 1 gene is 1 of the most overexpressed genes in human glioblastomas.
|
20499402 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence.
|
28430288 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future.
|
24842123 |
2014 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
|
18092325 |
2008 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Neither SAGE nor Northern analysis revealed the presence of HC gp-39 mRNA in the glioblastoma cell line, thus the detection of increased quantities of this mRNA in GBMs may be associated with activated macrophages.
|
12957359 |
2003 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well.
|
27121858 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001).
|
20224722 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resveratrol represses YKL-40 expression in human glioma U87 cells.
|
21029458 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.
|
31561550 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma.
|
31654711 |
2020 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stepwise multivariate Cox proportional hazards models were used, and the prognostic factors to significantly impact OS were: PFS < 54 weeks (HR: 5.86; CI: 3.02-11.33; p = 0.00); radiotherapy (HR: 0.34; CI: 0.18-0.60; p = 0.00); radio- and chemotherapy (HR: 0.05; CI: 0.03-0.10; p = 0.0), and YKL-40+ GBs (HR: 1.61; CI: 1.28-2.31; p = 0.01).
|
27179219 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Phospho-c-Jun activation by Anisomycin treatment in primary glioblastoma-derived cells attenuates the aggressive features of mesenchymal glioblastomas and leads to promoter methylation and downregulation of key mesenchymal genes (CD44, MMP9 and CHI3L1).
|
28036297 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis of glioma samples for YKL-40 protein levels revealed substantial elevation in approximately 65% of GBMs and undetectable levels in lower-grade gliomas (grade II and III) or normal brain tissue.
|
12154041 |
2002 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CHI3L2, IL1B, PI3/elafin and CHI3L1, which encodes for YKL-40, a putative prognosticator for various diseases, including cancer, were strongly up-regulated in avascular glioma.
|
18092325 |
2008 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas.
|
15788675 |
2005 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Even though TNF-alpha causes recruitment of p65 and p50 subunits of NF-kappaB to the YKL-40 promoter in all cell types, recruitment of histone deacetylases (HDAC)-1 and -2, and a consequent deacetylation of histone H3 at the YKL-40 promoter occurs only in glioma cells.
|
18708058 |
2008 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, targeting the CHI3L1 molecule may be a potential therapeutic molecular target for gliomas.
|
20506295 |
2011 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.
|
20224722 |
2010 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that CHI3L1 plays an important role in the regulation of malignant transformation and local invasiveness in gliomas.
|
20506295 |
2011 |